NCT06121349View on ClinicalTrials.gov

WOE of Anti-CD20 Therapies

CompletedOBSERVATIONAL
Enrollment

157

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

June 13, 2025

Study Completion Date

June 13, 2025

Conditions
Multiple Sclerosis
Interventions
DRUG

ocrelizumab

infusion therapy administered every six months

DRUG

ofatumumab

self-injectable every month

Trial Locations (1)

07936

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY